

Contents

Contributors

xi

Preface

xiii

1. The computational modeling of allosteric modulation of metabotropic glutamate receptors	1
Laura Pérez-Benito, Claudia Llinas del Torrent, Leonardo Pardo, and Gary Tresadern	
1. Introduction	2
2. Introduction to class C GPCRs	8
3. Structural aspects of mGlu receptors	10
4. Mutagenesis and structure-based modeling of mGlu receptor allosteric modulators	12
5. Ligand-based computational modeling of mGlu receptors	14
6. Computational study of mGlu ₂ receptor allosteric modulators	16
7. Computational study of mGlu ₅ receptor allosteric modulators	20
8. Water and mGlu allosteric modulators	22
9. Conclusion	24
Acknowledgments	25
Conflict of interest	25
References	25
2. Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators	35
Kirstie A. Bennett, John A. Christopher, and Benjamin G. Tehan	
1. Introduction	36
2. Interest in targeting the mGlu ₅ receptor in CNS disorders	38
3. mGlu ₅ receptor negative allosteric modulator clinical trials	38
4. Overview of the general mGlu receptor architecture	41
5. Rationale for targeting the allosteric sites of the mGlu ₅ receptor	42
6. Allosteric sites on the mGlu ₅ receptor: Pharmacological and mutagenesis studies	43
7. Allosteric sites on the mGlu ₅ receptor: X-ray crystal structure of the 7TM region	45
8. Structure-based drug design at mGlu ₅ : Discovery of HTL0014242	46

9. Further learnings from structural information: Selectivity between mGlu ₅ and mGlu ₁	50
10. Further learnings from structural information: Mode switching	51
11. Further learnings from structural information: Full receptor activation process	53
12. Conclusion	53
Conflict of interest	53
References	54
Further reading	58
 3. The function and allosteric control of the human sweet taste receptor	 59
Guy Servant, Terry Kenakin, Lan Zhang, Mark Williams, and Nicole Servant	
1. Introduction	60
2. The human sweet taste receptor and its ligands	61
3. Human sweet taste receptor binding sites and signal transmission within the heterodimer	63
4. Evaluation of sweetener synergy at the human sweet taste receptor	66
5. Identification of potent and efficacious PAMs for the human sweet taste receptor	69
6. Human sweet taste receptor inhibitors	73
7. Conclusion	76
Conflict of interest	77
References	77
 4. The different aspects of the GABA_B receptor allosteric modulation	 83
Julie Kniazeff	
1. Introduction	84
2. Pharmacologic allosteric modulation	88
3. The GABA _B receptor: An allosteric heterodimer	93
4. Oligomerization of the GABA _B receptor: A putative manner for further allosteric control?	99
5. Allosteric modulation of GABA _B receptor by protein partners?	103
6. Conclusion	106
Acknowledgments	106
Conflict of interest	107
References	107

5. RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors	115
Augen A. Pioszak and Debbie L. Hay	
1. Introduction	116
2. Discovery of RAMPs as accessory proteins for CLR and CTR	119
3. RAMP modulation of additional class B GPCRs	120
4. RAMP modulation beyond class B receptors	122
5. Mechanisms of RAMP modulation of CLR ligand binding	122
6. Mechanisms of RAMP modulation of CTR ligand binding	130
7. RAMP modulation of class B GPCR signaling	132
8. RAMPs in lower organisms	133
9. Drug development outlook for RAMP-CLR/CTR complexes	134
10. Conclusion	135
Acknowledgments	135
Conflict of interest	135
References	135
6. Strategies and considerations of G-protein-coupled receptor photopharmacology	143
Alice E. Berizzi and Cyril Goudet	
1. Introduction	144
2. Modality of photoactivable ligands	146
3. Modality of photoswitchable ligands	148
4. Design criteria for photoswitchable drug-like compounds	154
5. Advantages and considerations for future applications of photopharmacology to biological systems	158
6. Conclusion	166
Acknowledgments	166
Conflict of interest	166
References	166
Further reading	172
7. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology	173
Francis S. Willard, Joseph D. Ho, and Kyle W. Sloop	
1. Introduction	
2. The history of small molecule drug discovery	
3. Research to probe GLP-1R allosteric modulation	

4. The discovery of BETP	178
5. Covalent mechanism of action of BETP	179
6. The <i>in vitro</i> pharmacology of BETP	179
7. BETP as a cAMP biased GLP-1(9-36) and oxyntomodulin positive allosteric modulator	181
8. The structural basis of BETP action	184
9. Is BETP a useful tool for understanding GLP-1R pharmacology?	185
Acknowledgments	187
Conflict of interest	187
References	187
8. Allosteric modulation of metabotropic glutamate receptors in alcohol use disorder: Insights from preclinical investigations	193
Kari A. Johnson and David M. Lovinger	
1. Introduction	194
2. Experimental systems for studying mGlu receptor relevance to AUD	199
3. Group I mGlu receptors in preclinical models of alcohol exposure	205
4. Group II mGlu receptors in preclinical models of alcohol exposure	213
5. Group III mGlu receptors in preclinical models of alcohol exposure	218
6. Conclusion	219
Acknowledgments	220
Conflicts of interest statement	221
References	221
9. Allosteric modulation of muscarinic receptors in alcohol and substance use disorders	233
Leigh C. Walker and Andrew J. Lawrence	
1. Introduction	235
2. Acetylcholine	236
3. Animal models of drug addiction	239
4. mAChR expression in reward circuitry	241
5. Effects of drugs of abuse on mAChR expression	246
6. mAChR allosteric modulators	247
7. The utility of targeting mAChRs for preventing drug acquisition and maintenance	249
8. The utility of targeting mAChRs for extinction facilitation	253
9. Reinstatement of drug seeking	258
10. Conclusion	260
Acknowledgments	263
Conflict of interest statement	263
References	263

10. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?	277
Miriam Scarpa, Sarah Hesse, and Sophie J. Bradley	
1. Introduction	278
2. Muscarinic acetylcholine receptors (mAChRs)	280
3. M1 mAChR drug development	282
4. Disease modification potential of M1 mAChRs	294
5. Conclusion	298
Conflict of interest	300
References	300
Further reading	310